Bupropion for the treatment of nicotine dependence in spit tobacco users: A pilot study

Lowell C. Dale, Jon Owen Ebbert, Darrell R. Schroeder, Ivana T Croghan, Donna F. Rasmussen, Judith A. Trautman, Lisa Sanderson Cox, Richard D. Hurt

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Few pharmacological therapies have been shown to increase abstinence rates among spit tobacco (ST) users. Bupropion has been shown to be effective in increasing abstinence rates among smokers but has not been studied in ST users. Sixty-eight adult (aged ≥48 years old) regular users of ST who were motivated to stop using ST were enrolled in a randomized, double-blind, placebo-controlled pilot study of bupropion sustained release (SR) or placebo for 12 weeks. The primary endpoint was 1-week, biochemically confirmed point-prevalence tobacco abstinence rate at the end of treatment (week 12). Nicotine withdrawal symptoms and weight change were assessed. At the end of 12 weeks of therapy, the point-prevalence tobacco abstinence rate was 44% in the bupropion group and 26% in the placebo group (p = 0.064). At 24 weeks following initiation of medication, the point-prevalence abstinence rate was 29% for both groups. After 7 weeks of medication, subjects on bupropion reported significantly less (p≤0.034) nicotine withdrawal than placebo. The mean weight change from baseline to end of treatment was +0.7 ± 1.9 kg for bupropion and +4.4 ± 2.4 kg for placebo (p = 0.03). The 6-month weight change for continuously abstinent subjects was 3.4 ± 3.6 kg in the bupropion group and 6.2 ± 5.0 kg in the placebo group (p = 0.49). Bupropion may increase abstinence rates in ST users and appears to attenuate weight gain during ST abstinence. Larger randomized, controlled trials of bupropion for ST users are needed.

Original languageEnglish (US)
Pages (from-to)267-274
Number of pages8
JournalNicotine and Tobacco Research
Volume4
Issue number3
DOIs
StatePublished - Aug 2002

Fingerprint

Bupropion
Tobacco Use Disorder
Tobacco
Placebos
Therapeutics
Nicotine
Weights and Measures
Substance Withdrawal Syndrome
Weight Gain
Randomized Controlled Trials
Pharmacology

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

Bupropion for the treatment of nicotine dependence in spit tobacco users : A pilot study. / Dale, Lowell C.; Ebbert, Jon Owen; Schroeder, Darrell R.; Croghan, Ivana T; Rasmussen, Donna F.; Trautman, Judith A.; Cox, Lisa Sanderson; Hurt, Richard D.

In: Nicotine and Tobacco Research, Vol. 4, No. 3, 08.2002, p. 267-274.

Research output: Contribution to journalArticle

Dale, Lowell C. ; Ebbert, Jon Owen ; Schroeder, Darrell R. ; Croghan, Ivana T ; Rasmussen, Donna F. ; Trautman, Judith A. ; Cox, Lisa Sanderson ; Hurt, Richard D. / Bupropion for the treatment of nicotine dependence in spit tobacco users : A pilot study. In: Nicotine and Tobacco Research. 2002 ; Vol. 4, No. 3. pp. 267-274.
@article{f0cd3e95245d418d87eaa294a0b2d526,
title = "Bupropion for the treatment of nicotine dependence in spit tobacco users: A pilot study",
abstract = "Few pharmacological therapies have been shown to increase abstinence rates among spit tobacco (ST) users. Bupropion has been shown to be effective in increasing abstinence rates among smokers but has not been studied in ST users. Sixty-eight adult (aged ≥48 years old) regular users of ST who were motivated to stop using ST were enrolled in a randomized, double-blind, placebo-controlled pilot study of bupropion sustained release (SR) or placebo for 12 weeks. The primary endpoint was 1-week, biochemically confirmed point-prevalence tobacco abstinence rate at the end of treatment (week 12). Nicotine withdrawal symptoms and weight change were assessed. At the end of 12 weeks of therapy, the point-prevalence tobacco abstinence rate was 44{\%} in the bupropion group and 26{\%} in the placebo group (p = 0.064). At 24 weeks following initiation of medication, the point-prevalence abstinence rate was 29{\%} for both groups. After 7 weeks of medication, subjects on bupropion reported significantly less (p≤0.034) nicotine withdrawal than placebo. The mean weight change from baseline to end of treatment was +0.7 ± 1.9 kg for bupropion and +4.4 ± 2.4 kg for placebo (p = 0.03). The 6-month weight change for continuously abstinent subjects was 3.4 ± 3.6 kg in the bupropion group and 6.2 ± 5.0 kg in the placebo group (p = 0.49). Bupropion may increase abstinence rates in ST users and appears to attenuate weight gain during ST abstinence. Larger randomized, controlled trials of bupropion for ST users are needed.",
author = "Dale, {Lowell C.} and Ebbert, {Jon Owen} and Schroeder, {Darrell R.} and Croghan, {Ivana T} and Rasmussen, {Donna F.} and Trautman, {Judith A.} and Cox, {Lisa Sanderson} and Hurt, {Richard D.}",
year = "2002",
month = "8",
doi = "10.1080/14622200210153821",
language = "English (US)",
volume = "4",
pages = "267--274",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "3",

}

TY - JOUR

T1 - Bupropion for the treatment of nicotine dependence in spit tobacco users

T2 - A pilot study

AU - Dale, Lowell C.

AU - Ebbert, Jon Owen

AU - Schroeder, Darrell R.

AU - Croghan, Ivana T

AU - Rasmussen, Donna F.

AU - Trautman, Judith A.

AU - Cox, Lisa Sanderson

AU - Hurt, Richard D.

PY - 2002/8

Y1 - 2002/8

N2 - Few pharmacological therapies have been shown to increase abstinence rates among spit tobacco (ST) users. Bupropion has been shown to be effective in increasing abstinence rates among smokers but has not been studied in ST users. Sixty-eight adult (aged ≥48 years old) regular users of ST who were motivated to stop using ST were enrolled in a randomized, double-blind, placebo-controlled pilot study of bupropion sustained release (SR) or placebo for 12 weeks. The primary endpoint was 1-week, biochemically confirmed point-prevalence tobacco abstinence rate at the end of treatment (week 12). Nicotine withdrawal symptoms and weight change were assessed. At the end of 12 weeks of therapy, the point-prevalence tobacco abstinence rate was 44% in the bupropion group and 26% in the placebo group (p = 0.064). At 24 weeks following initiation of medication, the point-prevalence abstinence rate was 29% for both groups. After 7 weeks of medication, subjects on bupropion reported significantly less (p≤0.034) nicotine withdrawal than placebo. The mean weight change from baseline to end of treatment was +0.7 ± 1.9 kg for bupropion and +4.4 ± 2.4 kg for placebo (p = 0.03). The 6-month weight change for continuously abstinent subjects was 3.4 ± 3.6 kg in the bupropion group and 6.2 ± 5.0 kg in the placebo group (p = 0.49). Bupropion may increase abstinence rates in ST users and appears to attenuate weight gain during ST abstinence. Larger randomized, controlled trials of bupropion for ST users are needed.

AB - Few pharmacological therapies have been shown to increase abstinence rates among spit tobacco (ST) users. Bupropion has been shown to be effective in increasing abstinence rates among smokers but has not been studied in ST users. Sixty-eight adult (aged ≥48 years old) regular users of ST who were motivated to stop using ST were enrolled in a randomized, double-blind, placebo-controlled pilot study of bupropion sustained release (SR) or placebo for 12 weeks. The primary endpoint was 1-week, biochemically confirmed point-prevalence tobacco abstinence rate at the end of treatment (week 12). Nicotine withdrawal symptoms and weight change were assessed. At the end of 12 weeks of therapy, the point-prevalence tobacco abstinence rate was 44% in the bupropion group and 26% in the placebo group (p = 0.064). At 24 weeks following initiation of medication, the point-prevalence abstinence rate was 29% for both groups. After 7 weeks of medication, subjects on bupropion reported significantly less (p≤0.034) nicotine withdrawal than placebo. The mean weight change from baseline to end of treatment was +0.7 ± 1.9 kg for bupropion and +4.4 ± 2.4 kg for placebo (p = 0.03). The 6-month weight change for continuously abstinent subjects was 3.4 ± 3.6 kg in the bupropion group and 6.2 ± 5.0 kg in the placebo group (p = 0.49). Bupropion may increase abstinence rates in ST users and appears to attenuate weight gain during ST abstinence. Larger randomized, controlled trials of bupropion for ST users are needed.

UR - http://www.scopus.com/inward/record.url?scp=0036672286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036672286&partnerID=8YFLogxK

U2 - 10.1080/14622200210153821

DO - 10.1080/14622200210153821

M3 - Article

C2 - 12215235

AN - SCOPUS:0036672286

VL - 4

SP - 267

EP - 274

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 3

ER -